Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome

Cousins, Laura A.; Pericleous, Charis; Khamashta, Munther A.; Bertolaccini, Maria Laura; Ioannou, Yiannis; Giles, Ian; Rahman, Anisur

doi:10.1136/annrheumdis-2014-206483

Cited by 45 publications

(37 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-b2GPI IgA might even provide a marker of seronegative APS, since this test has been shown to identify patients with manifestations highly suggestive of APS, but no consensus aPLs [40][41][42].…”

Section: Resultsmentioning

confidence: 97%

Update on the pathogenesis and treatment of the antiphospholipid syndrome

Chighizola

Raschi

Borghi

et al. 2015

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 97%

Update on the pathogenesis and treatment of the antiphospholipid syndrome

Chighizola

Raschi

Borghi

et al. 2015

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…In a very recent report, the IgG anti-domain I b 2 GPI assay was positive in a significant proportion of seropositive patients with APS, but also in a small proportion (3/40) of seronegative APS patients (clinical features of APS but repeatedly negative in conventional aPL assays) [51]. The evaluation of anti-domain I b 2 GPI is very promising, but its clinical relevance must be confirmed in longitudinal, prospective studies to clarify its role [52].…”

Section: Antibodies To Domain I Of B 2 Gpimentioning

confidence: 88%

The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome

Forastiero

Martinuzzo

2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by clinical symptoms of vascular thrombosis and/or pregnancy morbidity in the presence of autoimmune antiphospholipid antibodies (aPL). Current laboratory APS criteria include the presence of at least one of the three relevant aPL: lupus anticoagulant, anticardiolipin antibodies and anti-β2 glycoprotein I antibodies. Therefore, patients could have a single aPL pattern or combinations of aPL. Evidence arising from clinical experience indicates that patients having the highest aPL titer and simultaneous aPL detected by different tests have a worse prognosis and a higher probability of recurrence of the APS clinical features. In recent years, an emerging role of multiple aPL positivity in the identification of high-risk patients with aPL/APS is evident. This paper will review the current knowledge on the clinical relevance of having single or multiple aPL positivity.

show abstract

“…While anti-D1 antibodies seem to be higher predictive for thrombotic manifestations than the test against the native molecule, anti-D1 assay displays a lower sensitivity suggesting that anti-D1 cannot substitute the standard test in the routine [47]. There are actually anecdotal reports of anti-D1 positivity with negativity ACCEPTED MANUSCRIPT…”

Section: Antibodies Directed To the Domain I Of 2gpimentioning

confidence: 99%

“…for anti-β2GPI molecule (and for other aPL), but the values were in the borderline area and further studies are necessary to investigate such an aspect [47].…”

Section: Accepted Manuscriptmentioning

confidence: 99%